| FY 2009 (No.257-) |
Japanese
version
issued
on |
No. |
Table of contents |
Posted
on |
PDF |
January 27, 2010
|
265 |
- 1.
- Handling of fire during Long-term Oxygen Therapy
- 2.
- Important Safety Information
- (1)
- Sorafenib tosilate
- (2)
- Aripiprazole, spiperone, sulpiride, zotepine, nemonapride, pipamperone hydrochloride, pimozide, moperone hydrochloride
- (3)
- Olanzapine, risperidone (oral dosage form), risperidone (injectable dosage form)
- (4)
- Quetiapine fumarate
- (5)
- Tandospirone citrate
- 3.
- Revision of PRECAUTIONS (No. 212)Acemetacin (and 14 others)
- 4.
- List of products subject to Early Post-marketing Phase Vigilance
|
Mar. 3, 2010 |
 |
December 25, 2009
|
264 |
- 1.
- Safety measures for anaphylaxis and anaphylactoid symptoms associated with injectable antibiotics
- 2.
- Important Safety Information
- (1)
- Salazosulfapyridine
- (2)
- Pethidine hydrochloride, pethidine hydrochloride/levallorphan tartrate
- 3.
- Revision of PRECAUTIONS (No. 211)Indometacin (oral dosage form) (and 7 others)
- 4.
- List of products subject to Early Post-marketing Phase Vigilance
|
Jan. 29, 2010 |
|
November 27, 2009 |
263 |
- 1.
- Association between use of human insulin and insulin analogues and risk of cancer
- 2.
- Important Safety Information.
- (1)
- Ivermectin
- (2)
- Everolimus, gusperimus hydrochloride, cyclosporine (oral dosage form, injectable dosage form), tacrolimus hydrate (oral dosage form, injectable dosage form), basiliximab (genetical recombination), mycophenolate mofetil, muromonab-CD3
- (3)
- Ciprofloxacin, ciprofloxacin hydrochloride
- (4)
- Sunitinib malate
- (5)
- Sorafenib tosilate
- (6)
- Tegafur/gimeracil/oteracil potassium
- (7)
- Bevacizumab (genetical recombination)
- (8)
- Rosuvastatin calcium
- 3.
- Revision of PRECAUTIONS (No. 210)
- (1)
- Pancuronium bromide, vecuronium bromide, rocuronium bromide (and 7 others)
- (2)
- Blood circuits (and 3 others)
- 4.
- List of products subject to Early Post-marketing Phase Vigilance
| Dec 24, 2009
|
|
October 28, 2009 |
262 |
- 1.
- PMDA Medical Safety Information
- 2.
- The Relief System for Sufferers from Adverse Drug Reactions and Disease Infected from Biological Products
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
| Nov 30, 2009
|
|
| September 29, 2009 |
261 |
- 1.
- Drug-induced serious skin disorders
- 2.
- SSRIs/SNRIs and harmful behavior to others
- 3.
- Important Safety Information
- (1)
- Varenicline tartrate
- 4.
- Revision of PRECAUTIONS (No. 209)
Cibenzoline succinate (oral dosage form) (and 7 others)
- 5.
- List of products subject to Early Post-marketing Phase Vigilance
(Reference Material)
-
- Reports on adverse reactions associated with influenza vaccines in FY 2008 (Conclusion of the Vaccine Adverse Reaction Review Committee)
|
Oct 29, 2009
|
|
| August 26, 2009 |
260 |
- 1.
- Tricyclic and tetracyclic antidepressants, associated with aggression
- 2.
- Important Safety Information
- (1)
- Telmisartan
- (2)
- Phenytoin, Phenytoin/Phenobarbital, Phenytoin/Phenobarbital/Caffeine and Sodium Benzoate, Phenytoin Sodium
- 3.
- Revision of PRECAUTIONS (No. 208)
Lamotrigine (and 9 others)
- 4.
- List of products subject to Early Post-marketing Phase Vigilance
|
Sep 10, 2009
|
|
| July 30, 2009 |
259 |
- 1.
- Important Safety Information
- (1)
- Monobasic Sodium Phosphate Monohydrate and Anhydrous Dibasic Sodium Phosphate
- 2.
- Revision of PRECAUTIONS (No. 207)
Blonanserin (and 4 others)
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
(Reference Material)
-
- About Oseltamivir Phosphate (Tamiflu)
< The brief summary of the review results of the investigation by the Subcommittee on Drug Safety (held on June 16, 2009)>
|
Sep 7, 2009
|
|
|
June 24, 2009 |
258 |
- 1.
- Selective serotonin reuptake inhibitors (SSRIs) and aggression
- 2.
- Important Safety Information
- (1)
- Isoflurane
- 3.
- Revision of PRECAUTIONS (No. 206)
Olmesartan medoxomil (and 3 others)
- 4.
- List of products subject to Early Post-marketing Phase Vigilance
(Reference Material)
-
-
- 1.
- Project for promoting safe use of drugs
- 2.
- Manuals for Management of Individual Serious Adverse Drug Reactions
- 3.
- Extension of cooperating hospitals in the project for "Japan Drug Information Institute in Pregnancy"
|
July 31, 2009
|
|
| May 28, 2009 |
257 |
- 1.
- Implementation of appropriate management/ maintenance of automated external defibrillators (AEDs)
- 2.
- Revision of PRECAUTIONS (No. 205)
Naproxen (and 7 others)
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
|
July 14, 2009
|
|
